Syncona Share News (SYNC)
SYNC Share
SYNC Share
SYNC Share
SYNC Share
SYNC
SYNC Share
SYNC Level 2
SYNC Live
SYNC Broker
SYNC Directors
SYNC Financial
SYNC
SYNC Short
SYNC
Last checked at -
To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.
Find out More
(Sharecast News) - Healthcare investment and development company Syncona announced on Tuesday that Freeline Therapeutics - a biotechnology company focussed on developing curative gene therapies for chronic systemic diseases - has raised a further $80m (£65.09m) from specialist global institutional investors in an expanded series C round.
Read more
DIRECTOR DEALINGS: Syncona Non-Exec Reverberi Buys GBP50,000 In Shares
Read moreFormer Bayer Healthcare Chief Medical Officer Malik Joins Syncona
Read moreSyncona Annual Assets Take Hit From Autolus Value But Likes Portfolio
Read more(Sharecast News) - Syncona reported a 13% fall in net asset value as the value of its life sciences division dropped by a quarter in its most recent financial year.
Read moreUK Earnings, Trading Statements Calendar - Next 7 Days
Read moreSyncona Investee Achilles Therapeutics Starts Melanoma Therapy Trial
Read more(Sharecast News) - Syncona announced on Friday that its portfolio company, Achilles Therapeutics, has dosed the first patient in a phase 1 and 2 clinical study of its clonal neoantigen T cell (cNeT) therapy, in patients with recurrent or metastatic malignant melanoma.
Read moreSyncona Makes USD51 Million Investment Into SwanBio Therapeutics
Read more(Sharecast News) - Syncona announced a new $51m (?41.39m) commitment in an expanded $77m series A round of financing by SwanBio Therapeutics on Thursday.
Read moreSyncona, Arix Note US FDA Acceptance Of Autolus Drug Application
Read more(Sharecast News) - Syncona revealed on Tuesday that chairperson Melanie Gee had acquired 26,500 ordinary shares in the FTSE 250-listed life sciences investor.
Read more(Sharecast News) - Syncona updated the market on its trading amid the Covid-19 coronavirus pandemic on Monday, reporting that since the start of the outbreak, it had taken measures to protect its employees, primarily centred around remote working, to help ensure it could continue to operate with as minimal disruption as possible.
Read moreSyncona Expects Delays In Clinical Trials Due To Virus Disruption
Read moreDIRECTOR DEALINGS SUMMARY: Plus500 Team Spend GBP14 Million On Shares
Read more
Last checked at